Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
(2019) Leukemia — Vol. 33, n° 10, p. 2531-2535 (2019)
Files
2019_Stilgenbauer_Leukemia.pdf
Open Access - Adobe PDF
- 156.78 KB
Details
- Authors
- Abstract
- To the Editor: Chronic lymphocytic leukemia (CLL) remains incurable for most patients, requiring repeated therapy [1]. The tetraspanin CD37 is predominantly expressed on mature B cells, with low-level expression on T cells, granulocytes, and monocytes, and is widely expressed in mature B-cell malignancies, including CLL [...]
- Affiliations
Citations
Stilgenbauer, S., Aurran Schleinitz, T., Eichhorst, B., Lang, F., Offner, F., Rossi, J.-F., Schroyens, W., Van Den Neste, E., Ysebaert, L., von Wangenheim, U., Ursula Kress, U., Blum, P., & Zenz, T. (2019). Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. Leukemia, 33(10), 2531-2535. https://doi.org/10.1038/s41375-019-0475-z (Original work published 2019)